GlassScriptPhysician profile
Amy S Drumheller
NPI 1699745588
$11,385.43
in general payments reported to CMS, 2019-2025
31 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $920 · 2021: $1,263 · 2022: $1,676 · 2023: $2,036 · 2024: $1,986 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,194 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,193.64 |
| Education | $330.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,597.87 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,011.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,006.84 | 2020-2025 | Tremfya, Stelara, Simponi |
| Amgen INC. | $633.84 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $612.22 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $593.69 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $570.43 | 2021-2025 | Dupixent |
| Pfizer INC. | $542.06 | 2019-2025 | |
| Galderma Laboratories, L.P. | $509.70 | 2019-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $504.63 | 2019-2025 | |
| Lilly USA, LLC | $504.12 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $440.16 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $358.20 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $314.78 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $211.05 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $174.23 | 2023-2025 | Zoryve |
| Almirall LLC | $117.76 | 2019-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $94.60 | 2020-2021 | |
| Dermavant Sciences, INC. | $90.03 | 2023-2024 | Vtama |
| Celgene Corporation | $75.48 | 2019 | |
| Mayne Pharma Commercial LLC | $56.84 | 2019-2021 | |
| Epi Health, LLC | $48.25 | 2020-2021 | |
| Organon LLC | $44.53 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $41.17 | 2019 | |
| Biofrontera INC. | $40.11 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $39.22 | 2023 | Puraply |
| Dermira, INC. | $37.33 | 2019 | |
| Lnhc, INC | $35.41 | 2025 | Zelsuvmi |
| Sanofi-Aventis U.S. LLC | $34.19 | 2020 | |
| Journey Medical Corporation | $23.63 | 2023 | |
| Prugen, INC. Pharmaceuticals | $21.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Drumheller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.